The discovery of the selective If current inhibitor ivabradine (Procoralan®): A new therapeutic approach to ischemic heart disease;La découverte de l'ivabradine (Procoralan®), inhibiteur sélectif du courant pacemaker If: Une nouvelle approche thérapeutique des cardiopathies ischémiques

Medecine/Sciences

Volumn 22, Issue 1, 2006, Pages 87-94

  Vilaine, Jean Paul ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IVABRADINE; NEW DRUG; PROPRANOLOL;

AGING; ATRIOVENTRICULAR CONDUCTION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG TOLERABILITY; EXERCISE; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART RATE; HEART REPOLARIZATION; HUMAN; INDUSTRIALIZATION; ISCHEMIC HEART DISEASE; MORTALITY; PREVALENCE; QUALITY OF LIFE; REVIEW; SINUS NODE; STABLE ANGINA PECTORIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 31144438644     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200622187     Document Type: Review

References (53)

1. Holubkov R, Laskey WK, Haviland A, et al. Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry. Am Heart J 2002; 144: 826-33.
2. Mannheimer C, Camici P, Chester MR, et al. The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J 2002; 23: 355-70.
3. Steg PG, Dabbous OH, Feldman LJ, et al. Determinants and pronostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 2004; 109: 494-9.
4. Freemantle N, Cleland J, Young P, et al. β blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J 1999; 318: 1730-7.
5. Dorgie HJ, Corucci W, Ford I, et al. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357:1385-90.
6. Janesi A, Ghali JK, Herlitz J, et al. Metoprolol CR/XL in postmyocardial infarction patients with chroic heart failure: Experiences from MERIT-HF. Am Heart J 2003; 146: 721-8.
7. Sonnenblick EH, Ross J Jr, Braunwald E. Oxygen consumption of the heart. Newer concepts of its multifactorial determination. Am J Cardiol 1968; 22: 328-36.
8. Vatner SF, Higgings CB, Franklin D, Braunwald E. Role of tachycardia in mediating the coronary hemodynamic response to severe exercice. J Appl Physiol 1972; 32: 380-5.
9. Nabel EG, Selwyn AP, Ganz P. Paradoxical narrowing of atherosclerotic coronary arteries induced by increases in heart rate. Circulation 1990; 81: 850-9.
10. Vatner SF, Baig H. Importance of heart rate in determining the effects of sympathomimetic amines on regional myocardial function and blood flow in conscious dogs with acute myocardial ischemia. Circ Res 1979; 45: 793-803.
11. Guth BD, Heusch G, Steitelberger R, et al. Mechanism of beneficial effect of β-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res 1987; 60: 738-46.
12. Dyer AR, Persky V, Stamler J, et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidermologic studies. Am J Epidemtol 1980; 112: 736-49.
13. Kannel WB, Kannel C, Paffengarger RS Jr, et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: 1489-94.
14. Hjalmarson A, Gilpin EA, Kjekshus JK, et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990; 65: 547-53.
15. Greenland P, Daviglus ML, Dyer AR, et al. Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago Heart Association Detection Project in industry. Am J Eptdemiol 1999; 149: 853-62.
16. Kristal-Boneh E, Silber H, Harari G, et al. The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS Study). Eur Heart J 2000; 21: 116-24.
17. Aronow WS, Ahn C, Mercando AD, et al. Association of average heart rate on 24-hour ambulatory electrocardiograms with incidence of new coronary events at 48-month follow-up in 1,311 patients (mean age 81 years) with heart disease and sinus rhythm. Am J Cardiol 1996; 78: 1175-6.
18. Diaz A, Bourassa MG, Guertin MC, et al. Long term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-74.
19. Kjekshus J. Importance of heart rate in determining beta-blocker efficacy in acute and long-term myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43F-9.
20. The Multicenter Diltiazem Postinfarction Trial Research Group. Effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385-92.
21. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-55.
22. CIBIS Investigators and Committees. A randomised trial of β-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-73.
23. Nul DR, Doval HC, Grancelli HO, et al. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol 1997; 29: 1199-205.
24. James R, Arnold J, Allen J, et al. The effects of heart rate, myocardial ischemia and vagal stimulation on the threshold of ventricular fibrillation. Circulation 1977; 55: 311-7.
25. Bermer M, Curtis JM, Hearse DJ. Ischemia-induced and reperfusion-induced arrhythmias: importance of heart rate. Am J Physiol 1989; 256: H21-31.
26. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984; 226: 180-2.
27. Kaplan JR, Manuck SB, Clarkson TB. The influence of heart rate on coronary atherosclerosis. J Cardiovasc Pharmacol 1987; 10: S100-2.
28. Beere PA, Glagov S, Zarins CK. Experimental atherosclerosis at the carotid bifurcation of the cynomolgus monkey. Localization, compensatory enlargement, and the sparing effect of lowered heart rate. Atheroscler Thromb 1992; 12: 1245-53.
29. Perski A, Hamsten A, Linvall K, et al. Heart rate correlates with severity of coronary artery atherosclerosis in young postinfarction patients. Am Heart J 1988; 116: 1369-73.
30. Perski A, Ollson G, Landou C, et al. Minimum heart rate and coronary atherosclerosis: Independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J 1992; 123: 609-16.
31. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-82.
32. Wright AJ, Hudlicka O. Capillary growth and changes in heart performance induced by chronic bradycardial pacing in the rabbit. Circ Res 1981; 49: 469-78.
33. Wright AJ, Hudlicka O, Brown MD. Beneficial effect of chronic bradycardial pacing on capillary growth and heart performance in volume overload heart hypertrophy. Circ Res 1989; 64: 1205-12.
34. Zheng W, Brown MD, Brock TA, et al. Bradycardia-induced coronary angiogenesis is dependent on vascular endothelial growth factor. Circ Res 1999; 85: 192-8.
35. Patel SR. Breal JA, Diver DJ, et al. Bradycardia is associated with development of coronary collaterals in humans. Coron Artery Dis 2000; 11: 467-72.
36. DiFrancesco D. Pacemaker mechanisms in cardiac tissue. Annu Rev Physiol 1993; 55: 451-67.
37. DiFrancesco D. The onset and autonomic regulation of cardiac pacemaker activity: relevance of the f current. Cardiovasc Res 1995; 29: 449-56.
38. f) by cAMP in the rabbit sino-atrial node. J Physiol 1994; 474: 473-82.
39. Heyndrickx GR, Pannier JL, Muylaert P, et al. Alteration in myocardial oxygen balance during exercise after β-adrenergic blockade in dogs. J Appl Physiol 1980; 49: 28-33.
40. Berdeaux A, Drieu la Rochelle C, Richard V, et al. Opposed responses of large and small coronary arteries to propranolol during exercise in dogs. Am J Physiol 1991; 261: H265-70.
41. Peglion JL, Vian J, Thollon C, et al. S 16257, a novel sinoatrial node modulator: potent bradycardic activity with improved specificity. Can J Physiol Pharmacol 1994; 72 (suppl 1): 95 (abstract).
42. Thollon C, Cambarrat C, Vian J, et al. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol 1994; 112: 37-42.
43. Thollon C, Bibouard JP, Cambarrat C, et al. Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. Eur J Pharmacol 1997; 339: 43-51.
44. Irisawa H, Brown HF, Giles W. Cardiac pacemaking in the sinoatrial node. Physiol Rev 1993; 73: 197-227.
45. Bois P, Bescond J, Renaudon B, et al. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 1996; 118: 1051-7.
46. Simon L, Ghaleh B, Puybasset L, et al. Coronary and haemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995; 275: 659-66.
47. Vilaine JP, Bidouard JP, Lesage L, et al. Anti-ischemic effects of ivabradine, a selective heart rate reducing agent, in exercise-induced myocardial ischemia in pigs. J Cardiovasc Pharmacol 2003; 42: 688-96.
48. Camm AJ, Lau CP. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs RD 2003; 4: 83-9.
49. Manz M, Reuter M, Lauck G, et al. A single intravenous dose of ivabradine, a novel I(f) inhibitor lowers heart rate but does not depress left ventricular in patients with left ventricular dysfunction. Cardiology 2003; 100: 149-55.
50. f inhibitor, in stable angina. A randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003; 107: 817-23.
51. f inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529-36.
52. f current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004; 109: 1674-9.
53. f, in ventricular myocytes from human failing heart. Circulation 1997; 95: 568-71.